blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP0991625

EP0991625 - INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  23.11.2012
Database last updated on 07.10.2024
Most recent event   Tooltip17.04.2015Change - lapse in a contracting state
New state(s): DE, ES, FR, GB, GR, IT, PT		published on 20.05.2015  [2015/21]
Applicant(s)For all designated states
Bristol-Myers Squibb Pharma Company
Lawrenceville-Princeton Road P.O. Box 4000
Princeton NJ 08543-4000 / US
[N/P]
Former [2003/18]For all designated states
Bristol-Myers Squibb Pharma Company
Lawrenceville-Princeton Road P.O. Box 4000
Princeton, New Jersey 08543-4000 / US
Former [2002/19]For all designated states
Bristol-Myers Squibb Pharma Company
203 Longmeadow Drive
Wilmington, DE 19810 / US
Former [2000/28]For all designated states
Dupont Pharmaceuticals Company
Chestnut Run Plaza, 974 Centre Road
Wilmington, DE 19805 / US
Former [2000/15]For all designated states
THE DU PONT MERCK PHARMACEUTICAL COMPANY
1007 Market Street
Wilmington, Delaware 19898 / US
Inventor(s)01 / GALEMMO, Robert, Anthony, Jr.
3039 Stump Hall Road
Collegeville, PA 19426 / US
02 / DOMINGUEZ, Celia
963 Cedar Cliff Court
Westlake Village, CA 91320 / US
03 / FEVIG, John, Matthew
987 Church Road
Lincoln University, PA 19352 / US
04 / HAN, Qi
2609 Marhill Drive
Wilmington, DE 19810 / US
05 / LAM, Patrick, Yuk-Sun
6 Ridgeway Drive
Chadds Ford, PA 19317 / US
06 / PINTO, Donald, Joseph, Philip
39 Whitson Road
Newark, DE 19702 / US
07 / PRUITT, James, Russell
237 Skycrest Drive
Landenberg, PA 19350 / US
08 / QUAN, Mimi, Lifen
113 Venus Drive
Newark, DE 19711 / US
[2000/15]
Representative(s)Beacham, Annabel Rose, et al
Dehns
St Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
[N/P]
Former [2002/23]Beacham, Annabel Rose, et al
Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Victoria Street
London EC4V 4EL / GB
Former [2000/15]Pett, Christopher Phineas, et al
Frank B. Dehn & Co., European Patent Attorneys, 179 Queen Victoria Street
London EC4V 4EL / GB
Application number, filing date98931355.618.06.1998
[2000/15]
WO1998US12681
Priority number, dateUS1997087888519.06.1997         Original published format: US 878885
US19980076691P27.02.1998         Original published format: US 76691 P
[2000/15]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO9857937
Date:23.12.1998
Language:EN
[1998/51]
Type: A2 Application without search report 
No.:EP0991625
Date:12.04.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 23.12.1998 takes the place of the publication of the European patent application.
[2000/15]
Type: B1 Patent specification 
No.:EP0991625
Date:01.06.2005
Language:EN
[2005/22]
Search report(s)International search report - published on:EP18.03.1999
ClassificationIPC:C07D231/00
[2000/15]
CPC:
C07D257/04 (EP); C07D213/16 (KR); A61P7/02 (EP);
C07D231/14 (EP); C07D277/56 (EP); C07D401/12 (EP);
C07D401/14 (EP); C07D403/12 (EP); C07D413/12 (EP) (-)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   NL,   PT,   SE [2000/15]
Extension statesLT22.11.1999
LV22.11.1999
RO22.11.1999
SI22.11.1999
TitleGerman:INHIBITOREN DES FAKTORS XA MIT EINER NEUTRALEN GRUPPE MIT P1-SPEZIFITÄT[2000/15]
English:INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP[2000/15]
French:INHIBITEURS DU FACTEUR Xa COMPRENANT UN GROUPE A SPECIFICITE P1 NEUTRE[2000/15]
Entry into regional phase22.11.1999National basic fee paid 
22.11.1999Designation fee(s) paid 
22.11.1999Examination fee paid 
Examination procedure04.01.1999Request for preliminary examination filed
International Preliminary Examining Authority: EP
22.11.1999Examination requested  [2000/15]
19.12.2000Despatch of a communication from the examining division (Time limit: M06)
01.08.2001Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
10.10.2001Reply to a communication from the examining division
21.05.2002Despatch of a communication from the examining division (Time limit: M06)
29.11.2002Reply to a communication from the examining division
22.04.2004Date of oral proceedings
06.05.2004Despatch of a communication from the examining division (Time limit: M02)
06.05.2004Minutes of oral proceedings despatched
13.07.2004Reply to a communication from the examining division
12.10.2004Communication of intention to grant the patent
18.03.2005Fee for grant paid
18.03.2005Fee for publishing/printing paid
Opposition(s)Opponent(s)01  01.03.2006    ADMISSIBLE
Pochart, François C/o Cabinet Hirsch & Associés
58 Avenue Marceau
75008 Paris / FR
 [N/P]
Former [2006/17]
Opponent(s)01  01.03.2006    ADMISSIBLE
Pochart, François
58 Avenue Marceau
75008 Paris / FR
05.04.2006Invitation to proprietor to file observations on the notice of opposition
12.12.2006Reply of patent proprietor to notice(s) of opposition
07.08.2008Despatch of a communication from the opposition division (Time limit: M04)
10.12.2008Reply to a communication from the opposition division
08.05.2009Despatch of minutes of oral proceedings
29.07.2009Date of oral proceedings
11.09.2009Cancellation of oral proceeding that was planned for 19.10.2009
21.09.2009Despatch of a communication from the opposition division (Time limit: M02)
19.10.2009Date of oral proceedings
19.11.2009Reply to a communication from the opposition division
22.02.2011Despatch of a communication from the opposition division (Time limit: M04)
18.08.2011Despatch of interlocutory decision in opposition
30.08.2011Legal effect of interlocutory decision in opposition
22.12.2011Despatch of communication that the patent will be maintained as amended
10.08.2012Despatch of communication that the patent will be revoked
20.08.2012Legal effect of revocation of patent [2012/52]
Request for further processing for:10.10.2001Request for further processing filed
10.10.2001Full payment received (date of receipt of payment)
Request granted
23.10.2001Decision despatched
Fees paidRenewal fee
22.11.1999Renewal fee patent year 03
13.06.2001Renewal fee patent year 04
12.06.2002Renewal fee patent year 05
12.06.2003Renewal fee patent year 06
14.06.2004Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT01.06.2005
BE01.06.2005
CH01.06.2005
FI01.06.2005
LI01.06.2005
NL01.06.2005
DK01.09.2005
SE01.09.2005
LU18.06.2006
IE19.06.2006
GB18.06.2011
IT18.06.2011
ES19.06.2011
FR30.06.2011
PT19.12.2011
DE03.01.2012
GR05.01.2012
[2015/21]
Former [2008/36]AT01.06.2005
BE01.06.2005
CH01.06.2005
FI01.06.2005
LI01.06.2005
NL01.06.2005
DK01.09.2005
SE01.09.2005
LU18.06.2006
IE19.06.2006
Former [2007/29]AT01.06.2005
BE01.06.2005
CH01.06.2005
FI01.06.2005
LI01.06.2005
NL01.06.2005
DK01.09.2005
SE01.09.2005
IE19.06.2006
Former [2006/26]AT01.06.2005
BE01.06.2005
CH01.06.2005
FI01.06.2005
LI01.06.2005
NL01.06.2005
DK01.09.2005
SE01.09.2005
Former [2006/22]AT01.06.2005
BE01.06.2005
CH01.06.2005
FI01.06.2005
LI01.06.2005
NL01.06.2005
SE01.09.2005
Former [2006/14]AT01.06.2005
BE01.06.2005
CH01.06.2005
FI01.06.2005
LI01.06.2005
SE01.09.2005
Former [2006/13]AT01.06.2005
BE01.06.2005
FI01.06.2005
SE01.09.2005
Former [2005/52]FI01.06.2005
SE01.09.2005
Former [2005/50]SE01.09.2005
Cited inInternational search[A]DE2701091  (COMMW SCIENT IND RES ORG) [A] 1-4* see table I, page 11, compounds no. 20-27 *;
 [X]EP0015140  (MONSANTO CO [US]) [X] 1 * example 4; claim 1 *;
 [A]US4226877  (ARENDSEN DAVID L) [A] 1-4,8 * see table I, compound V; column 3, lines 7-13; claims 1,9 *;
 [X]DE3420985  (BAYER AG [DE]) [X] 1-4 * see table 1, page 13, fourth compound from the bottom; page 14, fourth compound;; claim 1 *;
 [X]GB2149402  (LILLY CO ELI) [X] 1-4 * see examples 82,83,86-91,110,113,131,136 *;
 [X]DE3540839  (BAYER AG [DE]) [X] 1-4 * claims 1-3 *;
 [X]DE3633840  (HOECHST AG [DE]) [X] 1-4 * see table I, examples no. 38, 59-61, 91, 100, 103, 110, 247;; claim 1 *;
 [X]DE3706993  (BAYER AG [DE]) [X] 1 * claims 1-3 *;
 [X]EP0289879  (MITSUBISHI CHEM IND [JP]) [X] 1-4 * see table 1, page 20, compound 58; page 27, compound 139; table 2, page 30, compound 162 *;
 [X]EP0333131  (HOECHST AG [DE]) [X] 1-4 * see table I, page 9, examples 40-46,59, page 11, examples 100-106,119, page 13, examples 160-166,179, page 15, examples 220-226,239, page 17, examples 280-286, 299, page 19, examples 340-346,359, * * page 25, examples 520-526,539, page 27, examples 580-586,599, page 41, examples 1000-1006,1019 *;
 [X]EP0418845  (FUJISAWA PHARMACEUTICAL CO [JP]) [X] 1,8 * page 2, line 1 - line 22; claims 1,2,9-11 *;
 [X]DE4013723  (BASF AG [DE]) [X] 1 * page 9, line 62 - page 10, line 19; claim 1; table A *;
 [AD]EP0513387  (OTSUKA PHARMA CO LTD [JP]) [AD] 1,8 * page 3, line 20 - page 5, line 47; claim 1 *;
 [X]US5262412  (ASHTON WALLACE T [US], et al) [X] 1,8 * claims 1,2,4 *;
 [AD]WO9402477  (MERCK SHARP & DOHME [GB], et al) [AD] 1,8 * claims 1,8-10 *;
 [Y]WO9514683  (DU PONT MERCK PHARMA [US]) [Y] 1-4,8 * page 206 - page 266; claims 1,30 *;
 [Y]WO9514682  (DU PONT MERCK PHARMA [US]) [Y] 1-4,8 * abstract * * page 36 - page 38 * * claims 1,7 *;
 [DY]WO9518111  (DU PONT MERCK PHARMA [US]) [DY] 1-4,8 * page 147 - page 171; claims 1,11,22 *;
 [X]DE4405207  (BAYER AG [DE]) [X] 1 * examples 2,14,26; claim 1 *;
 [Y]US5446056  (WITYAK JOHN [US], et al) [Y] 1-4,8 * abstract *;
 [DY]US5463071  (HIMMELSBACH FRANK [DE], et al) [DY] 1-4,8 * column 23, line 1 - column 24, line 25; example -; claim 1 *;
 [AD]WO9628427  (BERLEX LAB [US], et al) [AD] 1,8 * abstract *;
 [Y]WO9637482  (DU PONT MERCK PHARMA [US]) [Y] 1-4,8 * abstract *;
 [DY]WO9638426  (DU PONT MERCK PHARMA [US]) [DY] 1-4,8 * page 188 - page 286; claims 1,49 *
by applicantEP0028489
 EP0293881
 EP0471651
 US5187157
 WO9514682
 US5446056
 WO9637482
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY, (1985), page 1418
    - The Chemistry of Heterocyclic Compounds, JOHN WILEY & SONS
    - The Chemistry of Heterocyclic Compounds, Weissberger, JOHN WILEY & SONS
    - DUNCIA, J. ORG. CHEM., (1991), pages 2395 - 2400
    - THOMAS, SYNTHESIS, (1993), pages 767 - 768
    - J. ORG. CHEM., (1993), vol. 58, pages 32 - 35
    - BIOORG. & MED. CHEM. LETT., (1996), vol. 6, pages 1015 - 1020
    - WEINREB, TETR. LETT., (1977), vol. 48, pages 4171 - 4174
    - CHEM. BER., (1961), vol. 94, page 1116
    - J. ORG. CHEM., (1976), vol. 41, page 1073
    - J. CHEM. SOC., (1935), page 899
    - TETR, (1974), vol. 30, page 409
    - CHEM. BER., (1979), vol. 112, page 1206
    - REGEL, E. ET AL., LIEBIGS ANN. CHEM., (1977), page 145
    - REGEL,E. ET AL., LIEBIGS ANN: CHEM., (1977), page 145
    - KETTNER ET AL., J. BIOL. CHEM., (1990), vol. 265, pages 18289 - 18297
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.